AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.
{iframe}http://www.businesswire.com/news/home/20160111005695/en/AstraZeneca-Moderna-Therapeutics-Announce-Collaboration-Co-Develop-Co-Commercialize{/iframe}